Skip to main content
Top
Published in: Rheumatology International 3/2023

Open Access 28-12-2022 | Thrombotic Thrombocytopenic Purpura | Case Based Review

Secondary immune-mediated thrombotic thrombocytopenic purpura in idiopathic inflammatory myopathy: a case-based review

Authors: Nikolas Ruffer, Marie-Therese Holzer, Lukas Can Bal, Simon Melderis, Martin Krusche, Tobias B. Huber, Ina Kötter

Published in: Rheumatology International | Issue 3/2023

Login to get access

Abstract

Immune-mediated thrombotic thrombocytopenic purpura (iTTP) is a potentially fatal acquired thrombotic microangiopathy syndrome that frequently develops in the context of infectious diseases or systemic autoimmune conditions including connective tissue diseases. We report the case of a 42-year-old female suffering from severe iTTP associated with anti-Jo-1 positive antisynthetase syndrome, which was successfully treated with combination therapy of intravenous immune globulin, rituximab and plasma exchange. Based on a systematic review of the literature, two additional cases of idiopathic inflammatory myopathy-associated iTTP (secondary iTTP) were identified. In conclusion, iTTP may be a rare complication of IIM that clinicians should consider in cases of marked thrombocytopenia. Further work-up of this finding should include a peripheral blood smear (schistocyte count) and ADAMTS13 activity. The concomitant manifestation of these autoimmune conditions may require intensive immunosuppressive therapy.
Literature
8.
go back to reference Sato T, Hanaoka R, Ohshima M, Miwa Y, Okazaki Y, Yajima N, Ishizashi H, Matsumoto M, Fujimura Y, Inokuma S (2006) Analyses of ADAMTS13 activity and its inhibitor in patients with thrombotic thrombocytopenic purpura secondary to connective tissue diseases: observations in a single hospital. Clin Exp Rheumatol 24(4):454–455PubMed Sato T, Hanaoka R, Ohshima M, Miwa Y, Okazaki Y, Yajima N, Ishizashi H, Matsumoto M, Fujimura Y, Inokuma S (2006) Analyses of ADAMTS13 activity and its inhibitor in patients with thrombotic thrombocytopenic purpura secondary to connective tissue diseases: observations in a single hospital. Clin Exp Rheumatol 24(4):454–455PubMed
9.
go back to reference Mannucci PM, Vanoli M, Forza I, Canciani MT, Scorza R (2003) Von Willebrand factor cleaving protease (ADAMTS-13) in 123 patients with connective tissue diseases (systemic lupus erythematosus and systemic sclerosis). Haematologica 88(8):914–918PubMed Mannucci PM, Vanoli M, Forza I, Canciani MT, Scorza R (2003) Von Willebrand factor cleaving protease (ADAMTS-13) in 123 patients with connective tissue diseases (systemic lupus erythematosus and systemic sclerosis). Haematologica 88(8):914–918PubMed
10.
go back to reference Rieger M, Mannucci PM, Kremer Hovinga JA, Herzog A, Gerstenbauer G, Konetschny C, Zimmermann K, Scharrer I, Peyvandi F, Galbusera M, Remuzzi G, Bohm M, Plaimauer B, Lammle B, Scheiflinger F (2005) ADAMTS13 autoantibodies in patients with thrombotic microangiopathies and other immunomediated diseases. Blood 106(4):1262–1267. https://doi.org/10.1182/blood-2004-11-4490CrossRefPubMed Rieger M, Mannucci PM, Kremer Hovinga JA, Herzog A, Gerstenbauer G, Konetschny C, Zimmermann K, Scharrer I, Peyvandi F, Galbusera M, Remuzzi G, Bohm M, Plaimauer B, Lammle B, Scheiflinger F (2005) ADAMTS13 autoantibodies in patients with thrombotic microangiopathies and other immunomediated diseases. Blood 106(4):1262–1267. https://​doi.​org/​10.​1182/​blood-2004-11-4490CrossRefPubMed
14.
go back to reference Bolko L, Didier K, Salmon J-H, Miyara M, Toquet S, Servettaz A, Allenbach Y, Benveniste O, Hervier B (2020) Anti-Jo1 Antibody Quantification Serve as a Prognostic Factor in Anti-synthetase Syndrom. Arthritis Rheumatol 72 Bolko L, Didier K, Salmon J-H, Miyara M, Toquet S, Servettaz A, Allenbach Y, Benveniste O, Hervier B (2020) Anti-Jo1 Antibody Quantification Serve as a Prognostic Factor in Anti-synthetase Syndrom. Arthritis Rheumatol 72
15.
Metadata
Title
Secondary immune-mediated thrombotic thrombocytopenic purpura in idiopathic inflammatory myopathy: a case-based review
Authors
Nikolas Ruffer
Marie-Therese Holzer
Lukas Can Bal
Simon Melderis
Martin Krusche
Tobias B. Huber
Ina Kötter
Publication date
28-12-2022
Publisher
Springer Berlin Heidelberg
Published in
Rheumatology International / Issue 3/2023
Print ISSN: 0172-8172
Electronic ISSN: 1437-160X
DOI
https://doi.org/10.1007/s00296-022-05260-8

Other articles of this Issue 3/2023

Rheumatology International 3/2023 Go to the issue
Live Webinar | 27-06-2024 | 18:00 (CEST)

Keynote webinar | Spotlight on medication adherence

Live: Thursday 27th June 2024, 18:00-19:30 (CEST)

WHO estimates that half of all patients worldwide are non-adherent to their prescribed medication. The consequences of poor adherence can be catastrophic, on both the individual and population level.

Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.

Prof. Kevin Dolgin
Prof. Florian Limbourg
Prof. Anoop Chauhan
Developed by: Springer Medicine
Obesity Clinical Trial Summary

At a glance: The STEP trials

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.

Developed by: Springer Medicine

Highlights from the ACC 2024 Congress

Year in Review: Pediatric cardiology

Watch Dr. Anne Marie Valente present the last year's highlights in pediatric and congenital heart disease in the official ACC.24 Year in Review session.

Year in Review: Pulmonary vascular disease

The last year's highlights in pulmonary vascular disease are presented by Dr. Jane Leopold in this official video from ACC.24.

Year in Review: Valvular heart disease

Watch Prof. William Zoghbi present the last year's highlights in valvular heart disease from the official ACC.24 Year in Review session.

Year in Review: Heart failure and cardiomyopathies

Watch this official video from ACC.24. Dr. Biykem Bozkurt discusses last year's major advances in heart failure and cardiomyopathies.